profit from every ₹100 of sales.
₹0₹100
Innova Captab
₹1,091.45+2.40% today
+51.8% in 1 year
1-year low ₹645.401-year high ₹1,299.35
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹44.32 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Innova Captab sold, what it kept, and what it did with the cash.
Sales went from ₹9.25 billion in 2023 to ₹16.0 billion in 2026, with ₹1.41 billion of profit last year.
SalesProfit
Innova Captab handed back 24% of the cash it generated last year.
₹114M
Free cash flow 2026₹482M
Bought back its own shares–
Paid as dividends₹114M
Cash vs. debt₹32M vs. ₹3.4B
Innova Captab vs. similar companies
Innova Captab grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Innova Captab | 44.3× · Expensive | ||
 Merck KGaA | 25.3× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive |
AI analysis
An AI analyst reads Innova Captab's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 9,254 | 10,770 | 12,344 | 16,039 | |
| 2,243 | 3,264 | 3,964 | 5,229 | |
| 1,052 | 1,415 | 1,655 | 1,872 | |
| 1,218 | 1,667 | 1,980 | 2,501 | |
| 680 | 943 | 1,283 | 1,409 | |
| 11.87 | 18.66 | 22.41 | – | |
| 24.2% | 30.3% | 32.1% | 32.6% | |
| 11.4% | 13.1% | 13.4% | 11.7% | |
| 7.3% | 8.8% | 10.4% | 8.8% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 7,044 | 13,209 | 15,804 | 18,374 |
| Cash | 35 | 117 | 155 | 32 |
| Total debt | 2,370 | 2,451 | 3,381 | 3,437 |
| Total liabilities | 4,279 | 4,900 | 6,210 | 7,466 |
| 2,765 | 8,309 | 9,594 | 10,908 | |
| 57 | 51 | 57 | – | |
| 17.0% | 11.1% | 10.5% | 11.3% | |
| 24.6% | 11.4% | 13.4% | 12.9% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 671 | 1,463 | 638 | 1,165 | |
| 790 | 2,874 | 1,725 | 684 | |
| -119 | -1,410 | -1,087 | 482 | |
| Dividends paid | – | – | – | 114 |
| – | – | – | – | |
| – | – | – | – |
Valuation
- 44.3×
- –
- –
- 5.0×
- 3.9×
- 129.7×
- 26.3×
- 0.8%
- 2.3%
- 0.2%
Profitability
- 32.6%
- 11.7%
- 8.8%
- –
- 10.7%
- 11.9%
- –
- –
- –
- –
Growth
- +20.1%
- –
- –
- –
- +0.0%
Financial health
- 1.4×
- 0.32
- –
- 12.3×
- 1.87
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 25%of 958
Top 44%of 888
Bottom 28%of 600
Top 28%of 889
Bottom 46%of 987
0.2%of the share price, paid each year
On $1,000 invested$2a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
8.1% of its profit
Room to growStretchedMore than it earns: 23.8%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
43No pass
Benjamin Graham
38No pass
Philip Fisher
42No pass
Peter Lynch
76Pass
Joel Greenblatt
8No pass
Charlie Munger
31No pass
Terry Smith
26No pass
Questions about Innova Captab
Is Innova Captab a good stock to buy?
A solid business, but the price is high. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Innova Captab AI analysis
What does Innova Captab do?
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Panchkula, India.
Does Innova Captab pay a dividend?
Yes. At today's price the dividend is 0.2% a year, about 8% of its yearly profit. In 2026 it paid out ₹114 million in dividends.
Is Innova Captab stock halal?
Yes. Innova Captab passes our halal screen: its business is permitted and its debt is 6% of its market value, under the 30% limit. How we check
How has Innova Captab stock done over the past year?
Up 51.8% over the past twelve months, to ₹1,091.45. It traded between ₹645.40 and ₹1,299.35 and is 16.0% below its high.
Who are Innova Captab's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Innova Captab's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.